Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ANL Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: April 29, 2026
Report Source: 2025 Annual Report
Adlai Nortye Ltd. Stock Analysis ANL
United States Health Care Small Cap Report: Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. The firm is involved in the research and development of pharmaceutical products. The company is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. The company is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. The company is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor and AN4035, a Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5).
Read More Adlai Nortye Ltd (ANL) Chart
Key Statistics of Adlai Nortye Ltd (ANL)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$10.12Volume
103.68KP/E Ratio (TTM)
-52 Week Range
Market Cap
454.40MAvg. Volume
116.60KDividend Yield
-Financial Metrics & Statements of Adlai Nortye Ltd (ANL)
FAQ's for Adlai Nortye Ltd (ANL)
- According to Musaffa’s Shariah screening methodology, Adlai Nortye Ltd (ANL) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Adlai Nortye Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Adlai Nortye Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Adlai Nortye Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Adlai Nortye Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Adlai Nortye Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.